Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K, Tanabe N, Suda R, Sasaki A, Matsumura A, Ema R, Kasai H, Kato F, Sekine A, Nishimura R, Jujo T, Sugiura T, Shigeta A, Sakao S, Tatsumi K.
Yamamoto K, et al. Among authors: ema r.
Respir Investig. 2017 Jul;55(4):270-275. doi: 10.1016/j.resinv.2017.04.004. Epub 2017 Jun 19.
Respir Investig. 2017.
PMID: 28705306